Fabrice Smieliauskas, PhD


Fabrice is a health economist and health services researcher who studies biomedical technologies, with a focus on three technologies in particular: precision cancer therapies, lung cancer screening, and orthopedic devices. One of his main research themes is the use of these classes of technologies and the value they provide to the health care system. A second theme is identifying systematic ways that three phases of technological change -- basic biological science, the development of new technologies, and use of technologies in the health care system – influence one another to accelerate or reduce translation of science to real-world clinical practice. These findings can serve to optimize the translational research enterprise.

Fabrice is co-Chair of the Cancer Policy and Outcomes Workgroup in the Comprehensive Cancer Center at the University of Chicago (http://cancerpolicy.uchicago.edu/), and teaches the core course of the Graduate Program in Health Administration and Policy while serving on its Advisory Board.


  • PhD (Health Policy), 2011, Harvard University
  • MA (Economics), 2001, University of Toronto - Toronto, Canada
  • BS (Mathematics and Economics), 2000, University of Toronto - Toronto, Canada



  • Shih YC, Xu Y, Liu L, Smieliauskas F. In Press. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. Journal of Clinical Oncology.
  • Witiw, C.D., L.A. Tetreault, F. Smieliauskas, B. Kopjar, E.M. Massicotte, M.G. Fehlings. 2017. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation. The Spine Journal. 17(1):15-25. http://www.sciencedirect.com/science/article/pii/S1529943016310221.
  • Smieliauskas, F. 2016. Conflicts of interest in medical technology markets: evidence from orthopedic surgery. Health Economics. 25(6):723-39. http://onlinelibrary.wiley.com/doi/10.1002/hec.3177/full.
  • Shih, Y.-C. T.*, F. Smieliauskas*, D.M. Geynisman, R.J. Kelly, T.J. Smith. 2015. Trends in the costs and utilization of targeted cancer therapies for the privately insured non-elderly: 2001-2011. Journal of Clinical Oncology. 33(19):2190-6. http://jco.ascopubs.org/content/33/19/2190.
  • Smieliauskas, F., S. Lam, D. Howard. 2014. Impact of negative clinical trial results for vertebroplasty on vertebral augmentation procedure rates. Journal of the American College of Surgeons. 219(3):525-533.e1. http://www.sciencedirect.com/science/article/pii/S1072751514003573.
  • Smieliauskas, F. *, C.-R. Chien*, C. Shen, D. M. Geynisman, Y.-C. T. Shih. 2014. Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review, Pharmacoeconomics. 32(7):651-80. http://link.springer.com/article/10.1007/s40273-014-0160-z.
  • Smieliauskas, F., H. MacMahon, R. Salgia, Y.-C. T. Shih. 2014. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. Journal of Medical Screening. 21(4):207-15. http://msc.sagepub.com/content/21/4/207.abstract
  • Geynisman, D.M.*, C.-R. Chien*, F. Smieliauskas, C. Shen, Y.-C. T. Shih. 2014. Economic Evaluation of Therapeutic Cancer Vaccines and Immunotherapy: a Systematic Review. Human Vaccines & Immunotherapeutics, 10(11):3415-24. https://www.landesbioscience.com/journals/vaccines/article/29407/
  • Shen, C., C.-R. Chien, D. M. Geynisman, F. Smieliauskas, Y.-C. T. Shih. 2014. A Review of Economic Impact of Targeted Oral Anticancer Medications. Expert Review of Pharmacoeconomics and Outcomes Research. 14(1):45-69. http://informahealthcare.com/eprint/TmT2rwDs8WVZUpIqDysv/full.
  • Shih Y.-C. T., Y. Xu, W. Dong, F. Smieliauskas,S. Giordano, Y. Shen. 2014. First Do No Harm: Population-Based Study Shows Non-Evidence-Based Trastuzumab Prescription May Harm Elderly Women with Breast Cancer. Breast Cancer Research and Treatment. 144(2):417-25. http://link.springer.com/article/10.1007%2Fs10549-014-2874-1.